Delving into the Latest Updates on Mosunetuzumab with Synapse

RegulationAccelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Conditional marketing approval (European Union), Priority Review (United States), Conditional marketing approval (China), Priority Review (China), Breakthrough Therapy (United States)

Login to view timeline

Structure/Sequence

Sequence Code 31212L

Source: *****

Sequence Code 616715439H

Source: *****

Sequence Code 616715440L

Source: *****

Sequence Code 651228354H

Source: *****

The goal of this study is to test mosunetuzumab given alone or in combination with a Bruton tyrosine kinase inhibitor (BTKi, such as ibrutinib, acalabrutinib, zanubrutinib, or pirtobrutinib) in participants with CLL (chronic lymphocytic leukemia) or small lymphocytic lymphoma (SLL).
The names of the study drugs in this research study are:
* Mosunetuzumab
* BTK inhibitor: Ibrutinib, acalabrutinib, zanubrutinib, or pirtobrutinib

Start Date24 Nov 2025

Sponsor / Collaborator

Dana-Farber Cancer Institute, Inc.

[+1]

100 Clinical Results associated with Mosunetuzumab

Login to view more data

100 Translational Medicine associated with Mosunetuzumab

Login to view more data

100 Patents (Medical) associated with Mosunetuzumab

Login to view more data

113

Literatures (Medical) associated with Mosunetuzumab

01 Feb 2026·CPT-Pharmacometrics & Systems Pharmacology

A Generalized Minimal PBPK ‐ PD Model of Bispecific Antibodies: Case Studies and Applications in Drug Development

Article

Author: Spinosa, Phillip ; Hosseini, Iraj ; Ramanujan, Saroja ; Joslyn, Louis ; Gadkar, Kapil

ABSTRACT:

Bispecific antibodies (bsAbs), for which each arm binds a distinct molecular target, are developed to engage soluble and cell surface targets in different therapeutic indications. Three key examples of mechanisms of action (MoA) for bsAbs are (1) immune cell engagers that foster immune cell interactions with target cells, (2) bispecifics that use one arm to increase specificity/localization to desired tissues to reduce on‐target off‐tissue toxicity, and (3) bispecifics that use two different arms to neutralize different disease targets. Understanding the pharmacokinetic (PK) profiles and target engagement of bsAbs poses unique challenges due to the existence of multiple targets with distinct biological properties. Here, we present a generalized minimal physiologically based pharmacokinetic (mPBPK) model to capture and predict the PK and target engagement of bsAbs across multiple tissues. First, we model the clinical PK and pharmacodynamic (PD) data for an anti‐IL‐13/IL‐17 bsAb to capture and explain the PD response in the soluble cytokine target levels. Second, we model and simulate the PK‐PD of the anti‐CD20/CD3 T cell engaging antibody, mosunetuzumab, which acts via trans‐binding between cell targets on B‐ and T‐lymphocytes. Third, we use the model to explore case studies for other bsAb approaches to demonstrate the impact of binding affinity and avidity on both PK and target engagement and to provide insights into drug design. Overall, our work yields a model with example applications to advance the use of mechanistic modeling for early PK and target engagement predictions as well as for optimization of bsAb design.

01 Jan 2026·BRITISH JOURNAL OF HAEMATOLOGY

Mosunetuzumab is effective and well tolerated in older patients with relapsed/refractory follicular lymphoma: Subgroup analysis of a phase I/II study

Article

Author: Budde, Lihua E. ; Zhou, Mingzhu ; Popplewell, Leslie L. ; Mei, Matthew ; Mun, Yong ; Thiruvengadam, Swetha Kambhampati ; Nikolaenko, Liana ; Zuo, Xiaofang ; Wei, Michael C. ; Wu, Mei ; Herrera, Alex F. ; Yin, Shen

Summary:

A high unmet need for novel, safe and effective therapies exists among older patients with non‐Hodgkin lymphoma (NHL). We report safety and efficacy of mosunetuzumab in a subgroup analysis of a phase I/II study, which examined the prognostic impact of age in 218 patients with relapsed/refractory (R/R) B‐cell NHL (B‐NHL; ≥65 years, n = 102; <65 years, n = 116) from the phase I expansion cohort (NCT02500407) and further evaluated 90 patients with R/R follicular lymphoma (FL; ≥65 years, n = 30; <65 years, n = 60) from the pivotal cohort. The most common adverse event (AE) was cytokine release syndrome, occurring less frequently in older versus younger (33.3% vs. 44.8%) patients with B‐NHL. Serious AEs were similar in older versus younger patients (45.1% vs. 46.6%). For patients with R/R FL, overall and complete response rates were numerically higher in older (86.7% and 70.0%, respectively) versus younger (76.7% and 55.0%) patients. Median progression‐free survival and time‐to‐next treatment were 17.9 months and not reached in older patients versus 12.0 and 18.1 months in younger patients. These findings demonstrate mosunetuzumab is effective and well‐tolerated across age groups in patients with R/R FL. Additional studies are warranted to further evaluate the safety and efficacy of mosunetuzumab in older patients with B‐NHL.

20 Dec 2025·JOURNAL OF CLINICAL ONCOLOGY

Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial

Article

Author: Kwan, Antonia ; Farias, Danielle ; Kim, Jin Seok ; Rubalcava, Luis ; Jeon, Young-Woo ; Min Kim, Tae ; Aizawa, Keiko ; Yamaguchi, Motoko ; Shah, Nikesh ; Budde, Lihua E. ; Aziz, Ashraf ; Liu, Steven ; Ead, Wahib S. ; Perez Zuniga, Juan Manuel ; Agreda Vasquez, Gladys Patricia ; Wu, Hao ; Issa, Samar ; Kondo, Tadakazu ; Mahuad, Carolina Valeria ; Khuhapinant, Archrob ; Wanitpongpun, Chinadol ; Wang, Jue ; Zhang, Huilai ; Turgut, Mehmet ; Ventura, Luz ; Olszewski, Adam ; Pavlovsky, Astrid ; Gulbas, Zafer ; Wei, Michael C. ; Li, Zhiming ; Goodgame, Boone ; Davies, Gwynivere ; Lampon, Gilberto Barranco ; Samanez, Cesar ; Maruyama, Dai ; Yin, Shen ; Bosch, Mark ; Kim, Won-Seog ; Farias, Joao ; Maral, Senem ; Rego, Eduardo ; Pham, Song ; Kim, Won Seog ; Fantl, Dorotea ; Hong, Huangming ; Alacacioglu, Inci ; Goto, Hideki ; Almaguer, David Gomez ; Lossos, Izidore ; Villa Cle, Diego ; Ashby, Joan ; Zhou, Xiaoxi ; Shen, Jianzhen ; Liu, Yanyan ; Rego, Eduardo M. ; Shin, Ho-Jin ; Doucet, Stephane ; Janousek, Martin ; Abadi, Uri ; Wudhikarn, Kitsada ; Kuruvilla, John ; Fesler, Mark ; Norasetthada, Lalita ; Olszewski, Adam J. ; Budde, Elizabeth ; Fogliatto, Laura Maria ; Abdulla, Nihal ; Batlevi, Connie L. ; Salganick, Jason ; Ozcan, Muhit ; To, Iris ; Custidiano, Maria ; Birhiray, Ruemu ; Fukuhara, Noriko ; Tong, Hongyan ; Kato, Koji ; Hu, Bei ; Lee, Myungwon ; Leão Cordeiro de Farias, Danielle ; Myint, Zaw ; Levi, Itai ; Westin, Jason ; Ogawa, Yoshiaki ; Avivi, Irit ; Yu, Li ; Kumode, Takahiro

PURPOSE:

Prognosis for patients with refractory/relapsed large B-cell lymphoma (LBCL) considered ineligible for curative-intent therapy is poor. The combination of mosunetuzumab, a T-cell–engaging bispecific antibody, and polatuzumab vedotin, an antibody-drug conjugate (Mosun-Pola), represents a novel fixed-duration outpatient therapy.

METHODS:

In the phase III SUNMO trial, patients with refractory/relapsed LBCL who were ineligible for autologous stem-cell transplant were randomly assigned (2:1) to receive Mosun-Pola or rituximab, gemcitabine, and oxaliplatin (R-GemOx). Dual primary end points were centrally assessed overall response rate (ORR) and progression-free survival (PFS). Overall survival was a key secondary end point.

RESULTS:

A total of 208 patients were randomly assigned to receive Mosun-Pola (n = 138) or R-GemOx (n = 70). At a median follow-up of 23.2 months, the primary analysis of SUNMO demonstrated that the median PFS was significantly longer with Mosun-Pola than with R-GemOx (11.5 months [95% CI, 5.6 to 18] v 3.8 months [95% CI, 2.9 to 4.1]; hazard ratio for progression or death, 0.41 [95% CI, 0.3 to 0.6]; P < .0001). ORR was significantly greater with Mosun-Pola versus R-GemOx (70% v 40%; P < .0001), with complete response rates of 51% and 24%, respectively. In the Mosun-Pola group, the rate of grade ≥2 cytokine release syndrome (CRS) and usage of tocilizumab occurred in <5% of patients and patient-reported outcomes were improved compared with R-GemOx.

CONCLUSION:

Mosun-Pola demonstrated superior efficacy versus R-GemOx, with significant improvements in both ORR and PFS, and infrequent CRS events with a manageable safety profile.

179

News (Medical) associated with Mosunetuzumab

05 Jan 2026

·www.pharmaceutical-technology.com

Sanofi and Earendil Labs forge $2.56bn autoimmune deal

Sanofi has penned a deal with US-based biotech startup Earendil Labs, which will see the company use its drug discovery platform to advance its autoimmune and inflammatory disease pipeline. Image credit: Below the Sky via ShutterStock.com. Ahead of JP Morgan 2026, pharmaceutical giant Sanofi has inked another deal with Helixon Therapeutics-affiliated startup Earendil Labs, which will see the pair collaborate on bispecific antibodies for autoimmune and inflammatory conditions. The agreement, which could be worth up to $2.56 bn, will see Sanofi utilise Earendil’s artificial intelligence (AI)-powered drug discovery platform to assist in the development of multiple autoimmune and inflammatory disease assets. Earendil’s platform incorporates predictive protein modelling with high-throughput experimental validation, which the biotech’s CEO, Jian Peng, says can assist in identifying new bispecifics and optimising their efficacy. Through this pact, Sanofi will hand over $160m in upfront and near-term payments, while agreeing to a potential further $2.4bn in development and commercial milestone payments in exchange for the global rights to any assets created from the collaboration. While Sanofi will retain the full rights to any therapies that reach the market, Earendil will be eligible to receive tiered royalties on net product sales, which will likely sit in the low double-digit range. Sanofi’s latest deal with Earendil follows the company’s agreement to buy the rights to two of its bispecific autoimmune assets – HXN-1002 for ulcerative colitis (UC) and Crohn’s disease and HXN-1003 for colitis and skin inflammation – for up to $1.8bn back in April 2025. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence This deal is the newest of a range of agreements that Sanofi has signed in recent months, with the company having handed over $1.7bn and $1.04bn in two separate licensing deals with Dren Bio and ADEL in December 2025. Sanofi also bolstered its vaccine pipeline back in December through a $2.2bn acquisition of hepatitis B jab manufacturer, Dynavax . This acquisition comes despite the US Center for Disease Control’s (CDC) recent decision to revoke the long-standing hepatitis B jab recommendation for infants, which was met with significant kickback from medical organisations. Bispecifics to break into the autoimmune sector As precision medicine continues to grow, companies are increasingly looking to develop therapies that can offer targeted efficacy. As a result, bispecific antibodies are gaining significant traction, as this modality offers enhanced precision over its monoclonal counterpart, which has been widely successful across the autoimmune sector. Roche is hoping that its oncology asset, Lunsumio (mosunetuzumab), will show benefit in systemic lupus erythematosus (SLE). The therapy is currently in a Phase II trial, which is set for completion near the end of 2028. Meanwhile, AbbVie is exploring the potential of its bispecific, lutikizimab, in a Phase III trial in hidradenitis suppurativa (HS) after the drug displayed promise in a mid-stage study. The drug is also in mid-stage trials for atopic dermatitis and UC. Hurdles to bispecific success in the autoimmune segment According to Vasilis Roumpelakis, associate director of Competitive Intelligence and Competitive Strategy at GlobalData, bispecifics could hold significant potential in the autoimmune market, but the evidence “remains early stage and selective”. “Their mechanistic case is compelling, as single-target therapies often hit a therapeutic ceiling, while bispecific antibodies may address this by engaging two distinct targets with a single molecule, potentially overcoming resistance and improving efficacy via enhanced tissue penetration and localised activity,” Roumpelakis said. Despite therapeutic promise, Roumpelakis noted that drugmakers must overcome substantial chemistry, manufacturing and control (CMC), regulatory and commercial hurdles that mAbs do not face. Heavy/light chain mispairing, as well as purification complexity, can pose significant manufacturing challenges, while their increased risk of immunogenicity is also notable, Roumpelakis added. “In contrast with oncology, the absence of validated predictive biomarkers represents a critical limitation constraining optimal deployment of bispecific antibodies in autoimmune diseases,” Roumpelakis added. While he believes that the widespread adoption of bispecifics in the autoimmune space is plausible, it will remain “contingent on successful proof-of-concept and Phase III studies, as well as the resolution of manufacturing and regulatory barriers”. GlobalData is the parent company of Pharmaceutical Technology . Pharmaceutical Technology Excellence Awards - Nominations Closed Nominations are now closed for the Pharmaceutical Technology Excellence Awards . A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact. Excellence in Action Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing , Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines. Discover the Impact

AcquisitionPhase 3License out/inVaccine

02 Jan 2026

·www.biospace.com

Vanda Ends 40-Year Motion Sickness Drug Drought with FDA Approval for Nereus

Gargonia/ iStock Jefferies analysts envision a steady launch curve that could ultimately drive meaningful sales from people who are dissatisfied with existing treatments. The FDA has approved Vanda Pharmaceuticals’ tradipitant for the prevention of vomiting induced by motion. The company filed for FDA approval after linking the oral neurokinin-1 receptor antagonist, which Vanda will sell as Nereus, to significant reductions in vomiting in two Phase III real-world provocation studies conducted on boats. In one trial, vomiting incidence was 18.3% to 19.5% with Nereus versus 44.3% with placebo. Vomiting rates were 10.4% to 18.3% with Nereus versus 37.7% on placebo in the second study. Vanda said the approval marks the first time in over 40 years that a new pharmacologic treatment for motion sickness has come to market. Nereus will compete with dramamine, an over-the-counter antihistamine drug that prevents and treats motion sickness symptoms including nausea, vomiting and dizziness. Jefferies analysts identified a detail of the approval that could differentiate Nereus. “Encouragingly, Nereus’ label is for the prevention of vomiting caused by motion, rather than the symptoms of motion sickness (e.g. nausea, vomiting, and dizziness) like dramamine,” the analysts said in a note to investors. The label permits patients to take Nereus around 60 minutes before an event expected to cause vomiting induced by motion. Patients need to take the medicine on an empty stomach, meaning at least one hour before or two hours after a full meal, but otherwise analysts said the “front page label looks clean/simple.” Vanda’s assessment of the market opportunity for Nereus includes two to three million U.S. patients who take dramamine every month, the analysts said. The lack of innovation in the motion sickness drug field means there may be some pent-up demand for Nereus. “We envision a steady launch curve as awareness builds over time, with some contribution from patients who have been waiting for an alternative to existing therapies,” the analysts said. “A modest penetration among dissatisfied users or patients who currently avoid travel (due to inadequate symptom control) could drive meaningful sales in theory.” Vanda is yet to share the list price for Nereus, but Jefferies analysts expect a premium over existing OTC treatments. The company hopes to be well prepared for launch ahead of the 2026 summer season, the analysts said, and plans to focus on digital advertising and direct-to-consumer outreach rather than building a large prescriber‑focused sales force. The analysts’ overview of the launch plan aligns with comments by Vanda CEO Mihael Polymeropoulos. On an earnings call in October 2025, Polymeropoulos described the strategy for both Nereus and jet lag drug Hetlioz. “We’re developing a quite elaborate strategy that will become very consumer-centric, focusing on concierge service for supplying the drug to both of them,” Polymeropoulos said. “Our recent experiences with direct-to-consumer campaigns, but also the elevation of brand awareness of the company, are going to be very important and have been strategically designed to be in place in advance of those launches.” The FDA could rule on Hetlioz in jet lag by Jan. 7. The back-to-back regulatory actions follow the creation of a collaborative framework to resolve disputes between the FDA and Vanda, which sued the agency in April amid rejections, a partial hold and other setbacks. The FDA lifted the partial hold on tradipitant last month. Vanda’s approval was one of a clutch of authorizations over the holiday period. The FDA also approved Agios Pharmaceuticals’ Aqvesme for the treatment of anemia in adults with alpha- or beta-thalassemia, and expanded the labels of Roche’s cancer drug Lunsumio and Boehringer Ingelheim’s pulmonary fibrosis medicine Jascayd .

Phase 3Drug ApprovalClinical Result

23 Dec 2025

·endpoints.news

Gilead's herpes deal; FDA approvals for Boehringer, Roche

Plus, news about BioMarin and Cassava. 💊 Gilead opts into Assembly Bio’s genital herpes programs: As a result, Gilead will pay Assembly $35 million based on a 2023 deal. The decision comes after Assembly reported Phase 1b data on two experimental treatments for recurrent genital herpes, ABI-1179 and ABI-5366, showing that each reduced lesions. Gilead called the data “potentially supportive of first new treatment for recurrent genital herpes in 25 years.” — Lei Lei Wu 🫁 FDA approves Boehringer Ingelheim’s Jascayd for second lung indication: The regulator cleared Jascayd to treat the progressive lung scarring condition called progressive pulmonary fibrosis. The drug received its first approval in October for idiopathic pulmonary fibrosis, marking the first new drug approved for that disease in over a decade. — Lei Lei Wu 💉 Roche gets accelerated approval of injectable Lunsumio: The FDA approved the injectable version of Roche’s CD20xCD3 bispecific under the brand name Lunsumio Velo for adult relapsed or refractory follicular lymphoma after at least two lines of therapy. European authorities had given the subcutaneous version of Lunsumio conditional approval last month. — Lei Lei Wu 🗑️ BioMarin scraps liver disease drug: The company said in an SEC filing it would stop development of BMN 349, which was being tested for Alpha-1 antitrypsin deficiency-associated liver disease. The move was disclosed just a few days after BioMarin said it would acquire Amicus for $4.8 billion. — Max Gelman. 💰Cassava settles class action lawsuit: The lawsuit, originally filed in 2021, involved “all purchasers or acquirers” of Cassava stock between Sept. 14, 2020, and Oct. 12, 2023. Cassava will pay $31.25 million to settle the lawsuit and said it admits no wrongdoing. — Max Gelman

Drug ApprovalClinical ResultAcquisitionPhase 1

100 Deals associated with Mosunetuzumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D11463	-	-	DB15434

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Recurrent Follicular Lymphoma	United States	Genentech, Inc.	22 Dec 2022
Refractory Follicular Lymphoma	United States	Genentech, Inc.	22 Dec 2022
Follicular Lymphoma	European Union	Roche Registration GmbH	03 Jun 2022
Follicular Lymphoma	Iceland	Roche Registration GmbH	03 Jun 2022
Follicular Lymphoma	Liechtenstein	Roche Registration GmbH	03 Jun 2022
Follicular Lymphoma	Norway	Roche Registration GmbH	03 Jun 2022

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Aggressive B-Cell Non-Hodgkin Lymphoma	NDA/BLA	Canada	Hoffmann-La Roche Ltd.	01 Jun 2025
Large B-cell lymphoma	Phase 3	Switzerland	Roche Holding AG	23 May 2023
B-cell lymphoma refractory	Phase 3	United States	Hoffmann-La Roche, Inc.	25 Apr 2022
B-cell lymphoma refractory	Phase 3	China	Hoffmann-La Roche, Inc.	25 Apr 2022
B-cell lymphoma refractory	Phase 3	Japan	Hoffmann-La Roche, Inc.	25 Apr 2022
B-cell lymphoma refractory	Phase 3	Argentina	Hoffmann-La Roche, Inc.	25 Apr 2022
B-cell lymphoma refractory	Phase 3	Brazil	Hoffmann-La Roche, Inc.	25 Apr 2022
B-cell lymphoma refractory	Phase 3	Canada	Hoffmann-La Roche, Inc.	25 Apr 2022
B-cell lymphoma refractory	Phase 3	Israel	Hoffmann-La Roche, Inc.	25 Apr 2022
B-cell lymphoma refractory	Phase 3	Mexico	Hoffmann-La Roche, Inc.	25 Apr 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05171647 (SUNMO, Pubmed \| J Clin Oncol)	Phase 3	-	452	Mosunetuzumab plus polatuzumab vedotin	sktyawmdrx(fbyieguvtb) = In the Mosun-Pola group, the rate of grade ≥2 cytokine release syndrome and usage of tocilizumab occurred in less than 5% of patients. bxsfiatker (btojrndlxu )	Positive	20 Dec 2025
				Rituximab + Gemcitabine + Oxaliplatin
NCT03671018 (ASH2025) Manual	Phase 1/2	B-cell lymphoma refractory Second line	80	Mosunetuzumab + Polatuzumab vedotin	vixuktjweu(lqxvvyhlkx) = otemeqxalo pwrdceuggo (yeayisxgqn, 61.6 - 89.2) View more	Positive	06 Dec 2025
				Rituximab + Polatuzumab vedotin	vixuktjweu(lqxvvyhlkx) = viecdiojhc pwrdceuggo (yeayisxgqn, 33.8 - 66.2) View more
NCT05169658 (ASH2025)	Phase 2	Follicular Lymphoma \| Marginal Zone B-Cell Lymphoma First line	42	Mosunetuzumab monotherapy	uipztrdfad(usyursbuaz) = jgzwprdvms otlsuezams (nkxmkegink ) View more	Positive	06 Dec 2025
ASH2025	Phase 2	Follicular Lymphoma \| Marginal Zone B-Cell Lymphoma First line	52	Mosunetuzumab	acvsbhflbv(uomcxwdpbj) = suljlgxgpj vvakonhwvw (jbcsrcohnd, 69 - 93) View more	Positive	06 Dec 2025
NCT05260957 (ASH2025)	Phase 2	Large B-cell lymphoma	25	Mosunetuzumab + Polatuzumab + Axicabtagene Ciloleucel	hcrbwzrdrb(hmhokriofe) = cwuuizrqqo ppklcbsqbt (gyuokvblkx ) View more	Positive	06 Dec 2025
NCT05207670 (MorningSun, ASH2025)	Phase 2	Follicular Lymphoma First line	101	Mosunetuzumab SC	jvcwiicyam(lqdipulsdj) = jmzyyndfmi jxzlqclnuv (iyixctccgm, 83.8 - 96.1) View more	Positive	06 Dec 2025
NCT05171647 (SUNMO, ASH2025)	Phase 3	Diffuse large B-cell lymphoma recurrent	208	Mosun-Pola	eyrabzptsw(unlydgpgwg) = Pts with Mosun-Pola had clinically meaningful improvements in mean scores by EORTC QLQ-C30 for constipation (C7, -10.2), while mean scores remained at baseline levels for pts in the R-GemOx arm. zlooafqbov (hdycfgctld ) View more	Positive	06 Dec 2025
				R-GemOx
NCT02500407 (ASH2025)	Phase 2	Follicular Lymphoma	94	Mosunetuzumab	wozchqmghw(sjvzlhxvaa) = n=1 frihclkvgb (kaawbxxlja ) View more	Positive	06 Dec 2025
				Mosunetuzumab (pts with a CR)
NCT04889716 (ASH2025)	Phase 2	Large B-cell lymphoma	8	Mosunetuzumab	efzzezxott(utppviyiva) = 1 patient received corticosteroids. 1 patient had a grade > 3 adverse event related to mosunetuzumab (2 episodes of grade 4 neutropenia, which responded to G-CSF and delay of mosunetuzumab) psvgtlymqc (ullfjmwlks )	Positive	06 Dec 2025
NCT05169515 (ASH2025)	Phase 1	B-cell lymphoma refractory	47	Mosunetuzumab (Mosun) in combination with golcadomide (Golca)	tqdovymoie(klskitcjmd) = neutropenia (57% and 58%), injection site reactions (57%; all Gr 1/2 in Arm 1 only), CRS (Gr 1/2: 43% and 33%, no Gr ≥3), rash (Gr ≥3: 3% and 0%), and infections (Gr ≥3: 11% and 8%). mpuavypoka (cvdwsotzyd )	Positive	06 Dec 2025
				glofitamab+golcadomide

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data